Cargando…

Intestinal Fibrosis in Inflammatory Bowel Disease and the Prospects of Mesenchymal Stem Cell Therapy

Intestinal fibrosis is an important complication of inflammatory bowel disease (IBD). In the course of the development of fibrosis, certain parts of the intestine become narrowed, significantly destroying the structure and function of the intestine and affecting the quality of life of patients. Chro...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yifei, Huang, Bin, Jin, Tao, Ocansey, Dickson Kofi Wiredu, Jiang, Jiajia, Mao, Fei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971815/
https://www.ncbi.nlm.nih.gov/pubmed/35370998
http://dx.doi.org/10.3389/fimmu.2022.835005
_version_ 1784679716506042368
author Wang, Yifei
Huang, Bin
Jin, Tao
Ocansey, Dickson Kofi Wiredu
Jiang, Jiajia
Mao, Fei
author_facet Wang, Yifei
Huang, Bin
Jin, Tao
Ocansey, Dickson Kofi Wiredu
Jiang, Jiajia
Mao, Fei
author_sort Wang, Yifei
collection PubMed
description Intestinal fibrosis is an important complication of inflammatory bowel disease (IBD). In the course of the development of fibrosis, certain parts of the intestine become narrowed, significantly destroying the structure and function of the intestine and affecting the quality of life of patients. Chronic inflammation is an important initiating factor of fibrosis. Unfortunately, the existing anti-inflammatory drugs cannot effectively prevent and alleviate fibrosis, and there is no effective anti-fibrotic drug, which makes surgical treatment the mainstream treatment for intestinal fibrosis and stenosis. Mesenchymal stem cells (MSCs) are capable of tissue regeneration and repair through their self-differentiation, secretion of cytokines, and secretion of extracellular vesicles. MSCs have been shown to play an important therapeutic role in the fibrosis of many organs. However, the role of MSC in intestinal fibrosis largely remained unexplored. This review summarizes the mechanism of intestinal fibrosis, including the role of immune cells, TGF-β, and the gut microbiome and metabolites. Available treatment options for fibrosis, particularly, MSCs are also discussed.
format Online
Article
Text
id pubmed-8971815
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89718152022-04-02 Intestinal Fibrosis in Inflammatory Bowel Disease and the Prospects of Mesenchymal Stem Cell Therapy Wang, Yifei Huang, Bin Jin, Tao Ocansey, Dickson Kofi Wiredu Jiang, Jiajia Mao, Fei Front Immunol Immunology Intestinal fibrosis is an important complication of inflammatory bowel disease (IBD). In the course of the development of fibrosis, certain parts of the intestine become narrowed, significantly destroying the structure and function of the intestine and affecting the quality of life of patients. Chronic inflammation is an important initiating factor of fibrosis. Unfortunately, the existing anti-inflammatory drugs cannot effectively prevent and alleviate fibrosis, and there is no effective anti-fibrotic drug, which makes surgical treatment the mainstream treatment for intestinal fibrosis and stenosis. Mesenchymal stem cells (MSCs) are capable of tissue regeneration and repair through their self-differentiation, secretion of cytokines, and secretion of extracellular vesicles. MSCs have been shown to play an important therapeutic role in the fibrosis of many organs. However, the role of MSC in intestinal fibrosis largely remained unexplored. This review summarizes the mechanism of intestinal fibrosis, including the role of immune cells, TGF-β, and the gut microbiome and metabolites. Available treatment options for fibrosis, particularly, MSCs are also discussed. Frontiers Media S.A. 2022-03-18 /pmc/articles/PMC8971815/ /pubmed/35370998 http://dx.doi.org/10.3389/fimmu.2022.835005 Text en Copyright © 2022 Wang, Huang, Jin, Ocansey, Jiang and Mao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Wang, Yifei
Huang, Bin
Jin, Tao
Ocansey, Dickson Kofi Wiredu
Jiang, Jiajia
Mao, Fei
Intestinal Fibrosis in Inflammatory Bowel Disease and the Prospects of Mesenchymal Stem Cell Therapy
title Intestinal Fibrosis in Inflammatory Bowel Disease and the Prospects of Mesenchymal Stem Cell Therapy
title_full Intestinal Fibrosis in Inflammatory Bowel Disease and the Prospects of Mesenchymal Stem Cell Therapy
title_fullStr Intestinal Fibrosis in Inflammatory Bowel Disease and the Prospects of Mesenchymal Stem Cell Therapy
title_full_unstemmed Intestinal Fibrosis in Inflammatory Bowel Disease and the Prospects of Mesenchymal Stem Cell Therapy
title_short Intestinal Fibrosis in Inflammatory Bowel Disease and the Prospects of Mesenchymal Stem Cell Therapy
title_sort intestinal fibrosis in inflammatory bowel disease and the prospects of mesenchymal stem cell therapy
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971815/
https://www.ncbi.nlm.nih.gov/pubmed/35370998
http://dx.doi.org/10.3389/fimmu.2022.835005
work_keys_str_mv AT wangyifei intestinalfibrosisininflammatoryboweldiseaseandtheprospectsofmesenchymalstemcelltherapy
AT huangbin intestinalfibrosisininflammatoryboweldiseaseandtheprospectsofmesenchymalstemcelltherapy
AT jintao intestinalfibrosisininflammatoryboweldiseaseandtheprospectsofmesenchymalstemcelltherapy
AT ocanseydicksonkofiwiredu intestinalfibrosisininflammatoryboweldiseaseandtheprospectsofmesenchymalstemcelltherapy
AT jiangjiajia intestinalfibrosisininflammatoryboweldiseaseandtheprospectsofmesenchymalstemcelltherapy
AT maofei intestinalfibrosisininflammatoryboweldiseaseandtheprospectsofmesenchymalstemcelltherapy